You are here: Home » News & Events » Quigley Pharma News Releases
Print this page

Quigley Pharma News Releases

12/03/09
QUIGLEY CEO, TED KARKUS, ANNOUNCES PHASE ONE OF 2010 STRATEGIC PLAN
07/22/09
QUIGLEY CORPORATION ANNOUNCES FINAL RESULTS OF QUIGLEY PHARMA'S PHASE IIB STUDY
07/17/09
TED KARKUS NAMED CEO OF THE QUIGLEY CORPORATION
07/10/09
DR. RICHARD ROSENBLOOM RESUMES SERVICES TO THE QUIGLEY CORPORATION’S PHARMA SUBSIDIARY
06/18/09
TED KARKUS APPOINTED INTERIM CHIEF EXECUTIVE OFFICER OF THE QUIGLEY CORPORATION
06/16/09
COLD-EEZE® LOZENGES NOT AFFECTED BY FDA ADVISORY FOR ZICAM® INTRA-NASAL PRODUCTS
06/15/09
Ted Karkus and Karkus Slate of Directors Prevail in Federal Court, Seated as Directors of The Quigley Corporation
06/12/09
Guy J. Quigley Resigns as Chairman and CEO
05/18/09
The Quigley Corporation Announces Update on Strategic Alternatives and Commitment to Additional Review of Current Cost Structure
11/12/08
Quigley Announces Completion of Phase IIb Clinical Study Of QR-333 For Diabetic Peripheral Neuropathy On November 25, 2008
09/16/08
Quigley Anti-Viral Compound QR448(a) Successfully Prevents Transmission of Infectious Bronchitis in Chickens
09/16/08
Quigley Announces Positive Follow Up Study of Poultry with Infectious Bronchitis
05/14/08
Quigley Announces Successful Poultry Study of Chickens with Infectious Bronchitis
09/11/07
Quigley Corporation Releases Update on Quigley Pharma's Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
08/01/07
Quigley Evaluates Regulatory and Market Opportunities for Anti-Inflammatory / Cytokine Modifying Compound
07/30/07
Quigley Begins Human Trial to Investigate Effects of Broad Spectrum Anti-Inflammatory Compound on Metabolic Syndrome Patients
06/20/07
Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases -- Human Study to Follow --
02/20/07
The Quigley Corporation and the Israeli Ministry of Agriculture (MOAG) Will Collaborate to Test Quigley Pharma QR-441(a) Broad Spectrum Anti-Viral Against Avian Flu H5N1 in Chickens
02/12/07
Quigley Granted Patent for Prophylactic and Anti-Transmissivity Uses of an Anti-Microbial Composition
01/22/07
Quigley QR-443 Cachexia Compound Demonstrates Dose Response Effectiveness in Second Preliminary Animal Model Study
01/08/07
Quigley’s Broad Spectrum Anti-Viral QR-441(a) Shown to be Effective Against Two Problematic Pathogens to the Poultry Industry
12/28/06
Quigley Announces Results of In-Vitro Studies for the Potential Treatment of Herpes Keratitis and Next Steps for Its QR-435 Compound
12/06/06
The Quigley Corporation to Present at the NYSSA Biotech/Specialty Pharma Conference
11/20/06
Quigley Pharma’s QR-333 Phase IIb Clinical Study Has Commenced
10/03/06
Quigley’s Radioprotective Compound QR-336 Shown to be Most Effective in Oral and Subcutaneous Injection Dose Forms in Animal Model Study
09/26/06
Following Positive Data Showing QR-333 to be Safe, Quigley Pharma to Proceed with Phase IIB Clinical Trials for Its Lead Investigational Compound Formulated for Diabetic Neuropathy
08/28/06
Quigley Launches Redesigned Quigley Pharma Web Site
08/21/06
Quigley Assigned Second Patent Covering Peripheral Neural and Vascular Ailments
08/08/06
Quigley Pharma Compound QR-443 Effective
07/12/06
Quigley Pharma Announces Continued Progress in Natural Broad Spectrum Anti-Viral for Use in Preventing Spread of Avian Flu in Poultry Stocks
05/22/06
Quigley to Conduct Further Testing of QR-435 for Ocular Herpes in Animals
Antiviral Efficacy and Toxicity Studies to be Conducted at
The Charles T. Campbell Ophthalmic Microbiology Laboratory, University of Pittsburgh
[More]
05/10/06
Quigley to Commence Medical Feed Poultry Study for Its QR-441(a) Investigational New Animal Drug Designed to Combat Avian Flu
Healthy Chicken study is the first in series of studies designed to determine
whether adding Active Ingredient to Chicken Feed will
reduce infectivity in potential H5N1 outbreak.
[More]
05/08/06
Quigley Pharma Scheduled to Commence Clinical Testing of QR-333, Its Topical Diabetic Peripheral Neuropathy Investigational New Drug
Pharmacokinetics Study at The Diabetes & Glandular Disease
Research Center in San Antonio slated for May 15th start date.
[More]
04/10/06
Quigley to Commence Human Testing of its QR-333 Topical Diabetic Peripheral Neuropathy Investigational New Drug
FDA Finalizes review cycle and gives Quigley go ahead to
begin Phase II studies under IND number 67,168
[More]
04/03/06
Quigley Enlists Leading Radiation Oncology Researcher to Assist in the Development Plan and Radiological Testing of QR-336 Compound
Company Plans to Develop Successful Animal Model to Comply with FDA
Animal Efficacy Rules for Radio-Protective Agents
[More]
03/21/06
Quigley Initiates Development Plan to Test QR-441(a) against Avian Flu in Poultry Stocks
Company enlists industry experts to assist in the design of INAD
(Investigational New Animal Drug) bird challenge studies.
[More]
03/07/06
Quigley Submits Investigational New Drug Application to the FDA for its QR-333 Diabetic Peripheral Neuropathy Compound
Filing Allows Quigley to Begin Human Clinical Trials
Following a 30 Day Review Period
[More]
02/13/06
Quigley Pharma Anti-Viral Compound QR-435 Demonstrates Potent Antiviral Activity Against Ocular and Genital Herpes
01/31/06
FDA Issues Investigational New Animal Drug (INAD) number to Quigley Pharma to Study Its Anti-Inflammatory Compound QR-440 on Arthritis in Dogs

[More]
01/23/06
Quigley Pharma's Scientific Advisory Board is Encouraged by Research Results; Strongly Supports Next Stage of Development

[More]
01/18/06
Quigley Pharma's Dr. Richard Rosenbloom to Present Results of Bird Flu Compound Research at Retroscreen Virology Conference
DOYLESTOWN, PA (January 18, 2006) The Quigley Corporation (NASDAQ: QGLY), announced today that Dr. Richard Rosenbloom, COO of Quigley Pharma, will be presenting the research results of the December 1, 2005 Mask Studies using Quigley Pharma's QR-441 compound at the upcoming conference, Bird Flu: The First Pandemic of the 21st Century. A Central Role for Antivirals.
[More]

^ Top

Previous page: Quigley Corporation Archived News
Next page: Quigley Pharma Archived News Releases